These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12090782)

  • 1. Onset of action following formoterol Turbuhaler and salbutamol pMDI in reversible chronic airway obstruction.
    Cazzola M; Grella E; Matera MG; Mazzarella G; Marsico SA
    Pulm Pharmacol Ther; 2002; 15(2):97-102. PubMed ID: 12090782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
    Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
    Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A; Szalai Z; Pullerits T; Radeczky E
    Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formoterol Turbuhaler 4.5 microg (delivered dose) has a rapid onset and 12-h duration of bronchodilation.
    Selroos O; Ekström T
    Pulm Pharmacol Ther; 2002; 15(2):175-83. PubMed ID: 12090792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol.
    Goldkorn A; Diotto P; Burgess C; Weatherall M; Holt S; Beasley R; Siebers R
    Respirology; 2004 Mar; 9(1):102-8. PubMed ID: 14982610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk).
    Benhamou D; Cuvelier A; Muir JF; Leclerc V; Le Gros V; Kottakis J; Bourdeix I
    Respir Med; 2001 Oct; 95(10):817-21. PubMed ID: 11601748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients.
    Rosenborg J; Larsson P; Rott Z; Böcskei C; Poczi M; Juhász G
    Eur J Clin Pharmacol; 2002 Jul; 58(4):S61-7. PubMed ID: 12214580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma.
    Kruse M; Rosenkranz B; Dobson C; Ayre G; Horowitz A
    Pulm Pharmacol Ther; 2005; 18(3):229-34. PubMed ID: 15707858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study.
    Cote C; Pearle JL; Sharafkhaneh A; Spangenthal S
    Pulm Pharmacol Ther; 2009 Feb; 22(1):44-9. PubMed ID: 19071226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients.
    Lötvall J; Ankerst J
    Respir Med; 2008 Mar; 102(3):449-56. PubMed ID: 18023335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility.
    Bouros D; Kottakis J; Le Gros V; Overend T; Della Cioppa G; Siafakas N
    Curr Med Res Opin; 2004 May; 20(5):581-6. PubMed ID: 15140323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial.
    Papi A; Corradi M; Pigeon-Francisco C; Baronio R; Siergiejko Z; Petruzzelli S; Fabbri LM; Rabe KF
    Lancet Respir Med; 2013 Mar; 1(1):23-31. PubMed ID: 24321801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
    Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease.
    Rosenkranz B; Rouzier R; Kruse M; Dobson C; Ayre G; Horowitz A; Fitoussi S
    Respir Med; 2006 Apr; 100(4):666-72. PubMed ID: 16303295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics.
    Rosenborg J; Bengtsson T; Larsson P; Blomgren A; Persson G; Lötvall J
    Eur J Clin Pharmacol; 2000 Aug; 56(5):363-70. PubMed ID: 11009043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma.
    Balanag VM; Yunus F; Yang PC; Jorup C
    Pulm Pharmacol Ther; 2006; 19(2):139-47. PubMed ID: 16009588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma.
    Boonsawat W; Charoenratanakul S; Pothirat C; Sawanyawisuth K; Seearamroongruang T; Bengtsson T; Brander R; Selroos O
    Respir Med; 2003 Sep; 97(9):1067-74. PubMed ID: 14509562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the bronchodilating effects of inhaled formoterol, salmeterol and salbutamol in asthmatic patients.
    Grembiale RD; Pelaia G; Naty S; Vatrella A; Tranfa CM; Marsico SA
    Pulm Pharmacol Ther; 2002; 15(5):463-6. PubMed ID: 12406669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD.
    Celli BR; Tashkin DP; Rennard SI; McElhattan J; Martin UJ
    Respir Med; 2011 Aug; 105(8):1176-88. PubMed ID: 21531124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
    Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
    Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.